She coleads a long-standing multidisciplinary UCSF-Makerere University research collaboration focusing on epidemiologic, clinical, translational, and implementation science studies of integrated population level approaches to HIV, TB, and noncommunicable diseases in Uganda in Kenya. Dr Chomont oversees studies to unravel the molecular mechanisms involved in HIV latency and to develop novel therapeutic strategies aimed at reducing the size of the HIV reservoir.
She is engaged in the design, implementation, and scale-up of HIV and related programs and research in the US and globally. Research Focus: The prevention and management of HIV, integration of HIV and tuberculosis interventions, and advancing implementation science that aims at generating knowledge and experiences in pursuit of the health of populations. Her work includes clinical trials of antiretroviral drug efficacy, testing strategies to optimize treatment outcomes, and evaluating models of HIV care and service delivery.
Research Focus: Prevention and treatment of HIV infection and related diseases in infants, children, and adolescents. She is a physician-scientist whose research utilizes innovative sequencing and molecular techniques to identify, enumerate, and characterize the viruses that establish productive infection, circulate during active infection, maintain persistence on therapy, and rebound from latency.
Working in primary human samples and the nonhuman primate model, her lab is currently focused on studying the viral and immune dynamics of rebound from latency and the use of broadly neutralizing antibodies in this context.
Research Focus: Basic mechanisms and translational impact of HIV transmission, pathogenesis, and persistence. Over the past 15 years, her research has focused on interventions for HIV and sexually transmitted infection STI treatment and prevention.
